1. Home
  2. Directory
  3. California
  4. Orange
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1235624321

DR. DALLAS JOSEPH DE LA VARA MD
Prescription History 1235624321
Psychiatry & Neurology - Neurology in Orange, CA

NPI Status: Active since June 29, 2018

Contact Information

101 THE CITY DR S
ORANGE, CA
ZIP 92868
Phone: (714) 456-8888

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DALLAS JOSEPH DE LA VARA MD, an active Neurology specialist practicing in Orange, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 55 documented patient claims. Among these therapy options, the most frequently utilized medication is Aimovig Autoinjector, which accounts for 15 claims alone.

Medication Index

A
N
T
U
No matching medications currently found on file.

Aimovig Autoinjector

Generic Formulation: Erenumab-AooeSpecialty: Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 20.4
Days Supply 606
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills34.7
Peer Average Days Supply1,030
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,025.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,068.33

State Avg Cost Per Claim

$956.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to help prevent migraine. This medication may work by changing the amounts of certain natural substances in the brain. Erenumab belongs to a class of drugs known as monoclonal antibodies. Preventing frequent migraine attacks can help improve your ability to concentrate and do your usual tasks.

Nurtec Odt

Generic Formulation: Rimegepant SulfateSpecialty: Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 347
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.0
Peer Average Days Supply674
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,341.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,689.41

State Avg Cost Per Claim

$1,324.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent or treat migraine. Rimegepant may work by changing the amount of a certain natural substance in the brain. It helps to relieve headache, pain, and other migraine symptoms (such as nausea, vomiting, sensitivity to light/sound). Prompt treatment helps you return to your normal routine and may decrease your need for other pain medications.

Topiramate

Generic Formulation: TopiramateSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 33.0
Days Supply 990
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills49.2
Peer Average Days Supply1,435
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $129.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.81

State Avg Cost Per Claim

$19.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.

Therapeutic Applications

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and decrease how often you get them. Topiramate will not treat a migraine headache once it occurs. If you get a migraine headache, treat it as directed by your doctor (such as by taking pain medication, lying down in a dark room). Topiramate is known as an anticonvulsant or antiepileptic drug.

Ubrelvy

Generic Formulation: UbrogepantSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 253
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply644
Conservative Utilization

This provider writes prescriptions for this formulation 44.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,060.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,147.21

State Avg Cost Per Claim

$1,151.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat migraine. Ubrogepant may work by changing the amount of a certain natural substance in the brain. It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting, sensitivity to light/sound). Prompt treatment helps you return to your normal routine and may decrease your need for other pain medications. This medication is not used to prevent future migraines or lessen how often you get migraines.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DALLAS JOSEPH DE LA VARA MD provides transparency into local medical care patterns within Orange, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.